Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SPDR Series Trust SPDR S&P Biotech ETF (NY:XBI)

77.17 -5.48 (-6.63%)
Official Closing Price Updated: 8:00 PM EDT, May 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about SPDR Series Trust SPDR S&P Biotech ETF

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Capricor Therapeutics Stock Tumbles After FDA Confirms Intent To Hold Advisory Committee Meet For Deramiocel Approval: But Retail’s Optimistic
The U.S. FDA stated that its review committee has identified no significant deficiencies and is on track to make a decision on the application by its deadline of the end of August. 
Via Stocktwits
Topics Economy Government
Exposures Economy Political Product Safety
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising... 
Via Talk Markets
Topics ETFs Stocks / Equities
Summit Therapeutics Stock Slumps After Partner Akeso Gets FDA Nod For Cancer Drug: Retail’s Optimistic
The company’s lead candidate, ivonescimab, aimed at treating certain cancers, was discovered by Akeso and is currently in multiple late-stage clinical trials. 
Via Stocktwits
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Immunovant Announces Roivant President Eric Venker As New CEO: Retail’s Elated
Immunovant stated that these changes are part of its parent entity, Roivant, increasing operational involvement and strategic oversight of the company. 
Via Stocktwits
Topics Government Retirement Stocks
Exposures Pension Political US Equities
uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic
The new designation is in addition to the existing Regenerative Medicine Advanced Therapy, Orphan Drug, and Fast Track designations granted to AMT-130. 
Via Stocktwits
Topics Bankruptcy
Exposures Financial Legal Product Safety
Why Summit Therapeutics Rallied Double Digits Today on Another Down day for the Markets
Via The Motley Fool
Topics ETFs
Is It A Good Time To Trade Small Cap Biotech Stocks? - 3 Steps To Consider
Large cap healthcare stocks have outperformed other sectors during the 2025 Tariff induced sell-off but they still have risks as one can see by Friday’s 5% decline. 
Via Talk Markets
Topics ETFs Stocks / Equities
Biotech Weakness Ahead?
Out of 50,000 posts, I’m not sure I’ve ever mentioned the sector fund XBI before, but here we are. It seems to me that this fund, representing the biotech sector, is in for some serious skidding. 
Via Talk Markets
Topics ETFs
Biotech Stocks Dive After Trump Tacks On 20% European Tariff. Why AbbVie, Merck Could Be Exposed.
It's unclear whether pharmaceutical goods could be exempt from tariffs. A number of drugmakers manufacture ingredients abroad. 
Via Investor's Business Daily
Topics Economy Government World Trade
Exposures Political Supply Chain Tariff
Retail Traders Mostly Bullish On Biotech Stocks Amid Blow From RFK Jr. Purge On Health Agencies
The sector's recent slide follows Peter Marks' resignation last week as the Food and Drug Administration's top vaccine regulator following a clash with Kennedy. 
Via Stocktwits
Topics ETFs Government
Exposures COVID-19 Political Product Safety
Biotech Stocks Take Another Beating As 'Chaos' Reigns At FDA With Reports Of Mass Firings
Reports of mass firings include another high-profile official as Robert F. Kennedy Jr. and Marty Makary take up their new roles. 
Via Investor's Business Daily
Topics Workforce
Exposures COVID-19 Layoff Product Safety
Moderna, Novavax Shares Are Tumbling Monday: What's Going On?
Vaccine stocks are trading lower Monday following a shakeup at the U.S. Food and Drug Administration. 
Via Benzinga
Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns
Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies. 
Via Investor's Business Daily
Exposures Product Safety
Soleno Therapeutics Stock Rockets 34% Pre-Market After FDA Approves Prader-Willi Syndrome Drug: Retail Sentiment Peaks
The company expects the drug, the first approved therapy to address hyperphagia in PWS patients, to be available in the U.S. starting April 2025. 
Via Stocktwits
Exposures Product Safety
Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Giving Up
Jefferies acknowledged acute liver failure could signal a new safety risk but maintained that the high unmet need for DMD treatments supports the bull case. 
Via Stocktwits
Capricor Therapeutics Stock Surges After Q4 Results Beat Estimates: Retail Gets More Bullish
The company said its available cash, cash equivalents, and marketable securities will be sufficient to cover the expenses and capital requirements into 2027. 
Via Stocktwits
Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon
A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved. 
Via Stocktwits
Sangamo Therapeutics Retail Traders Keep The Faith Even As Stock Slides After-Hours On Q4 Miss
Several optimistic users expressed confidence in the company securing a third potential agreement with a major pharma for its adeno-associated virus (AAV) capsid, STAC-BBB. 
Via Stocktwits
Healthcare Stocks Doing Well But SMID Biotech Looking A Little Frazzled
Small caps took another step down this past week as geopolitical events dampened sentiment. 
Via Talk Markets
Topics ETFs Stocks / Equities
SpringWorks Therapeutics Leads Biotech Pack In Weekly Retail Follower Surge: What's Fueling Interest?
Investor attention is now on whether Merck will confirm a formal offer as speculation over a potential acquisition continues dominating discussions around the stock. 
Via Stocktwits
Healthcare Sector Trying To Bounce Back
I often discuss highly rated stocks that are part of highly rated sectors. Thus, this time is a departure from the norm. Let's dive into the data for the healthcare sector. 
Via Talk Markets
Topics ETFs Stocks / Equities
Capricor Therapeutics’ Retail Chatter Explodes On Stocktwits After FDA Grants Priority Review For DMD Therapy
The health agency has accepted Capricor's Biologics License Application for full approval of deramiocel as a treatment for Duchenne muscular dystrophy cardiomyopathy. 
Via Stocktwits
Exposures Product Safety
Is It Time To Shift Focus To Beaten-Down Healthcare Stocks As Volatility Soars?
Healthcare performed terribly in 2023 and 2024, falling while the market was soaring. Year-to-date, the sector has outperformed. Is it time to focus on the stocks and ETFs of this low-Beta sector as... 
Via Talk Markets
Topics ETFs Stocks / Equities
Biotech Rally Coming In Weeks Ahead?
Large cap biopharma and MedTech stocks are leading the healthcare sector higher. 
Via Talk Markets
Topics ETFs Stocks / Equities
Emergent BioSolutions Stock Sinks As Q4 Revenue Plunges 30%, But Retail Clings To Profit Swing
For the first quarter, Emergent forecasted revenue in the range of $200 million to $240 million, lower than an analyst estimate of $279 million. 
Via Stocktwits
Adma Biologics' Retail Traders Eye Higher Open After Blowout Q4, Strong Full-Year Outlook
CEO Adam Grossman highlighted a 65% year-over-year jump in total revenue and a staggering 309% increase in adjusted EBITDA for 2024. 
Via Stocktwits
Retail Bets TG Therapeutics Stock Can Sustain Post-Earnings Gains Throughout The Week
Annual revenue from its MS drug, Briumvi, more than tripled, with U.S. net product revenue reaching $103.6 million in the fourth quarter and $310 million for the full year. 
Via Stocktwits
Altimmune Retail Buzz Heats Up On MASH Progress, FDA Nod For New Trials: Stock Jumps After Q4 Print
The company plans to unveil details at its virtual R&D Day on March 13. 
Via Stocktwits
Exposures Product Safety
MannKind Stock Surges After-Hours On Q4 Revenue Beat, Debt Reduction As Retail Investors Celebrate ‘Amazing Comeback’
The company significantly reduced its debt principal by $236 million, leaving just $36 million in remaining convertible debt, and ended 2024 with $203 million in cash, cash equivalents, and... 
Via Stocktwits
Arcutis Biotherapeutics Sees 400% Spike In Retail Buzz As Q4 Beat Fuels After-Hours Rally
Sales of Zoryve, Arcutis' leading dermatology drug, surged 413% year-over-year to $69.4 million, a 55% increase from the previous quarter. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.